LONDON (ShareCast) - (Sharecast News) - Pharmaceutical services company Open Orphan has secured a contract with Codagenix to conduct a first in-human trial evaluating the safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 vaccine candidate.
Open Orphan said on Tuesday that the first in-human Phase I study of CodaVax-Covid, a codon deoptimized SARS-CoV-2 single-dose, intranasal vaccine candidate, would be trialled at hVIVO's state-of-the-art quarantine facility in Whitechapel in London, in early Autumn.

The AIM-listed group said initial data from the study was expected by the end of 2020.

Chief executive Cathal Friel said: "We are proud to be conducting this Phase I study for Codagenix, a leader in their field, as it will help bring a promising vaccine candidate to the public to help combat the Covid-19 pandemic as quickly as possible.

"Codagenix's expertise in viral design technology, combined with hVIVO's Phase I trial capability, gives us confidence that this trial will be successful and a step forward for the world as it seeks to develop a Covid-19 vaccine to bring the pandemic to a close."

As of 1030 BST, Open Orphan shares were up 4.28% at 13.40p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE